Could early markers unlock treatments for a rare childhood disease?
NCT ID NCT07709728
First seen Jul 16, 2026 · Last updated Jul 17, 2026 · Updated 1 time
Summary
This study follows babies and young children (up to age 5) who have a genetic diagnosis of ataxia telangiectasia (A-T), a rare disease that affects movement and immunity. Researchers use brain and lung scans, blood tests, and movement analysis to spot early signs of disease progression. The goal is to find reliable markers that could be used in future trials of early-life treatments.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this study could identify early signs of disease progression in young children with ataxia telangiectasia, paving the way for future treatments that start before symptoms appear.
- What could go wrong
- This is an observational study, not a treatment trial. It may not find clear markers, and results might not apply to all children with A-T.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATAXIA TELANGIECTASIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Experimental drug shows promise for rare genetic disorder
- Large study looks at how a 25-Gene cancer test affects patients and families
- Continued EryDex treatment studied in rare neurological disorder
- Could red blood cells deliver a steroid to ease a rare brain disorder?
- Precision genetic therapy aims to slow rare brain disease
- New study hopes to outsmart pancreatic cancer by gathering clues